1. Home
  2. HCWB vs CELU Comparison

HCWB vs CELU Comparison

Compare HCWB & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$2.66

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$0.77

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
CELU
Founded
2018
2016
Country
United States
United States
Employees
N/A
115
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
17.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
HCWB
CELU
Price
$2.66
$0.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$35.00
$6.00
AVG Volume (30 Days)
93.4K
89.8K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.37
N/A
Revenue
$4,099,750.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.56
52 Week High
$7.35
$4.30

Technical Indicators

Market Signals
Indicator
HCWB
CELU
Relative Strength Index (RSI) 43.29 52.65
Support Level $0.37 $0.69
Resistance Level $3.89 $0.85
Average True Range (ATR) 0.35 0.06
MACD -0.26 0.01
Stochastic Oscillator 3.05 61.76

Price Performance

Historical Comparison
HCWB
CELU

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

About CELU Celularity Inc.

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

Share on Social Networks: